Estelle Chetrit1, Yvan L'homme2, Jagdip Singh Sohal2, Caroline Quach3. 1. Infectious Disease Division, Department of Pediatrics and Medical Microbiology, The Montreal Children's Hospital, McGill University, Montreal; 2. Canadian Food Inspection Agency, St Hyacinthe Laboratory, St Hyacinthe; 3. Infectious Disease Division, Department of Pediatrics and Medical Microbiology, The Montreal Children's Hospital, McGill University, Montreal; ; Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec.
Abstract
BACKGROUND: A publicly funded, group A rotavirus (RVA) vaccination program was implemented in Quebec in November 2011. OBJECTIVES: To evaluate trends in RVA infections and describe circulating genotypes before the implementation of a publicly funded vaccination program. METHODS: The Montreal Children's Hospital (Montreal, Quebec) virology laboratory database was reviewed for RVA ELISA performed between July 2006 and June 2011. A five-week moving average was used to follow the proportion of positive RVA ELISA test results. A season was defined as starting with the first two and ending with the final two consecutive weeks in which the percentage of specimens testing positive for RVA was ≥10%. Duplicate tests were excluded. A random sample of 39 RVA-positive fecal samples from the final season (2010/2011) was genetically characterized: VP4, VP6, VP7 and NSP4 gene segments were genotyped using sequence analysis. RESULTS: Of the 3403 nonduplicate tests, 433 were RVA positive: 15.1% (2006/2007) to 9.3% (2010/2011) of the samples were positive during the study period, with a proportionally larger decrease in the percentage of positive tests compared with the decrease in the number of tests performed. The most common RVA strain types detected were G9P[8]I1 (n=19) and G1P[8]I1 (n=14), followed by G2P[4]I2 (n=4), G3P[6]I1 (n=1) and G4P[8]I2 (n=1). Mixed RVA infection was observed in two samples. CONCLUSION: Before the implementation of the vaccination program, the proportion of positive RVA tests had already begun to steadily decline. The present study was the first to report the genetic makeup of human RVA collected from a Canadian hospital based on the genotyping of four gene segments. The present study provided a baseline with which to monitor the impact of the universal vaccination program.
BACKGROUND: A publicly funded, group A rotavirus (RVA) vaccination program was implemented in Quebec in November 2011. OBJECTIVES: To evaluate trends in RVA infections and describe circulating genotypes before the implementation of a publicly funded vaccination program. METHODS: The Montreal Children's Hospital (Montreal, Quebec) virology laboratory database was reviewed for RVA ELISA performed between July 2006 and June 2011. A five-week moving average was used to follow the proportion of positive RVA ELISA test results. A season was defined as starting with the first two and ending with the final two consecutive weeks in which the percentage of specimens testing positive for RVA was ≥10%. Duplicate tests were excluded. A random sample of 39 RVA-positive fecal samples from the final season (2010/2011) was genetically characterized: VP4, VP6, VP7 and NSP4 gene segments were genotyped using sequence analysis. RESULTS: Of the 3403 nonduplicate tests, 433 were RVA positive: 15.1% (2006/2007) to 9.3% (2010/2011) of the samples were positive during the study period, with a proportionally larger decrease in the percentage of positive tests compared with the decrease in the number of tests performed. The most common RVA strain types detected were G9P[8]I1 (n=19) and G1P[8]I1 (n=14), followed by G2P[4]I2 (n=4), G3P[6]I1 (n=1) and G4P[8]I2 (n=1). Mixed RVA infection was observed in two samples. CONCLUSION: Before the implementation of the vaccination program, the proportion of positive RVA tests had already begun to steadily decline. The present study was the first to report the genetic makeup of human RVA collected from a Canadian hospital based on the genotyping of four gene segments. The present study provided a baseline with which to monitor the impact of the universal vaccination program.
Authors: Jim P Buttery; Stephen B Lambert; Keith Grimwood; Michael D Nissen; Emma J Field; Kristine K Macartney; Jonathan D Akikusa; Julian J Kelly; Carl D Kirkwood Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: Julie A Boom; Jacqueline E Tate; Leila C Sahni; Marcia A Rench; Jennifer J Hull; Jon R Gentsch; Manish M Patel; Carol J Baker; Umesh D Parashar Journal: Pediatrics Date: 2010-01-18 Impact factor: 7.124
Authors: Jelle Matthijnssens; Max Ciarlet; Erica Heiman; Ingrid Arijs; Thomas Delbeke; Sarah M McDonald; Enzo A Palombo; Miren Iturriza-Gómara; Piet Maes; John T Patton; Mustafizur Rahman; Marc Van Ranst Journal: J Virol Date: 2008-01-23 Impact factor: 5.103
Authors: Stephen B Lambert; Cassandra E Faux; Lisa Hall; Frances A Birrell; Karen V Peterson; Christine E Selvey; Theo P Sloots; Michael D Nissen; Keith Grimwood Journal: Med J Aust Date: 2009-08-03 Impact factor: 7.738
Authors: Jon R Gentsch; Jennifer J Hull; Elizabeth N Teel; Tara K Kerin; Molly M Freeman; Mathew D Esona; Dixie D Griffin; Brittany P Bielfelt-Krall; Krisztian Banyai; Baoming Jiang; Margaret M Cortese; Roger I Glass; Umesh D Parashar Journal: J Infect Dis Date: 2009-11-01 Impact factor: 5.226
Authors: Xiaoli L Pang; Bonita Lee; Nasim Boroumand; Barbara Leblanc; Jutta K Preiksaitis; Charlotte C Yu Ip Journal: J Med Virol Date: 2004-03 Impact factor: 2.327
Authors: Jailson B Correia; Manish M Patel; Osamu Nakagomi; Fernanda M U Montenegro; Eliane M Germano; Nancy B Correia; Luis E Cuevas; Umesh D Parashar; Nigel A Cunliffe; Toyoko Nakagomi Journal: J Infect Dis Date: 2010-02-01 Impact factor: 5.226